- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04196842
Heart Failure Precision Medicine Study
February 1, 2022 updated by: University of California, Davis
The study aims to test the hypothesis that multi-omics studies can identify Heart Failure profiles at risk of adverse outcomes and evaluate a telemonitoring intervention in the optimization of guideline-directed medical therapy.
Study Overview
Detailed Description
In the US, the estimated prevalence of Heart Failure (HF) is 6.2 million and increasing.
The mortality approaches 50% within 5 years of diagnosis and HF is the main cause of hospitalization among patients over 65 years of age.
Information on molecular states may enhance understanding of causes and pathophysiological processes, improve risk prediction, identify new therapeutic targets, and improve subclassification for targeted therapy.
Time-dependent phenomapping has been used to identify clinical and genomic differences in a longitudinal fashion, which provides a mechanistic link underlying pathophysiology of the disease and associated outcomes.
Studies including high-throughput molecular approaches (multi-omics) along with time-dependent phenomapping would likely be even more powerful.
The overarching hypothesis of the study is that the integration of Multi-Omics studies with clinical variables can be implemented to identify patients at risk of adverse outcomes.
To test this hypothesis we propose: (1) Longitudinal profiling based on clinical data; (2) Longitudinal Multi-Omics Profiling; and (3) randomized of a telemonitoring intervention (Sensor Profiling) and the effectiveness in the optimization of guideline-directed medical therapy.
To achieve these aims we propose to: (1) recruit a cohort of 1000 participants; (2) perform cardiovascular clinical characterization from electronic medical records; (3) perform multi-omics studies and (4) randomization of a telemonitoring intervention in the optimization of guideline-directed medical therapy.
Proving these hypotheses would identify different meaningful clinical groups of patients within a cohort of patients with similar clinical conditions, health care providers would have a better understanding of the heterogeneity of the disease and the need for different preventive and therapeutic approaches in the context of precision medicine.
Study Type
Interventional
Enrollment (Anticipated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Erick S Romero, MD
- Phone Number: (916) 703-2071
- Email: esromero@ucdavis.edu
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- UC Davis Medical Center
-
Contact:
- Erick Romero, MD
- Phone Number: 916-703-2071
- Email: esromero@ucdavis.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of Heart failure
- Objective evidence of cardiac abnormality of structure or function (abnormal ECHO) or elevated levels of B-type natriuretic peptide (>100 pg/ml)
- HF stage B-D and class I-IV
Exclusion Criteria:
- Patients unable to consent
- Inability to comply with the protocol and follow-up requirements
- Patients unable to use a smartphone
- Patients assessed irregularly (less than two visits in one year)
- History of HTx
- Use of Mechanical circulatory support device (MCSD)
- Comorbidities that, according to the PI, have the potential to interfere with the interpretation of the results
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Telemonitoring
Blood pressure and heart rate monitoring, scale, activity tracker.
|
Set of telemonitoring devices: heart rate and blood pressure monitor, scale and activity tracker.
|
NO_INTERVENTION: No intervention
No intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of adverse outcomes in heart failure
Time Frame: Five years from enrollment
|
Rate of Mortality (all cause), hospitalization, Mechanical circulatory support device (MCSD) or heart transplant (HTx)
|
Five years from enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease progression
Time Frame: Five years from enrollment
|
Disease severity (ACC/AHA Heart Failure classification system)
|
Five years from enrollment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of guideline-directed medical therapy (GDMT).
Time Frame: One year from enrollment
|
Percentage of GDMT target doses
|
One year from enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Martin Cadeiras, MD, University of California, Davis
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
October 16, 2019
Primary Completion (ANTICIPATED)
January 16, 2024
Study Completion (ANTICIPATED)
October 16, 2025
Study Registration Dates
First Submitted
November 12, 2019
First Submitted That Met QC Criteria
December 10, 2019
First Posted (ACTUAL)
December 12, 2019
Study Record Updates
Last Update Posted (ACTUAL)
February 17, 2022
Last Update Submitted That Met QC Criteria
February 1, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1471560
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
Clinical Trials on Telemonitoring devices
-
Hospital Universitario 12 de OctubreConsorcio Centro de Investigación Biomédica en Red (CIBER)Recruiting
-
Asten SanteSlb Pharma; Withings; NouvéalRecruiting
-
Aalborg University HospitalAalborg University; Steno Diabetes Center NordjyllandRecruiting
-
Chang Hee, LeePurdue University; LG Electronics Inc.CompletedHypertensionKorea, Republic of
-
ResMedCompleted
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Societat Catalana de Pneumologia...RecruitingNon Invasive VentilationSpain
-
Istituto Auxologico ItalianoRecruiting
-
humanITcareUniversity of Barcelona; Hospital Universitario de Torrevieja; European Innovation...RecruitingHeart FailureSpain, Romania
-
Research and Practical Clinical Center for Diagnostics...Sechenov UniversityEnrolling by invitationInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisRussian Federation
-
Hospital Universitari de BellvitgeInstitut d'Investigació Biomèdica de BellvitgeCompleted